A novel hypurgia for cancer chemotherapy: Programmable release of antineoplastics and cytothesis agents from core-shell micro-/nano-particles.
As one of the main cancer therapeutic methods, chemotherapy plays a vital role in clinical practice. However, when killing the cancerous cells, the chemotherapy drugs also damage the normal cells. Side effects are still urgent problems to be solved. Cytothesis agents, like hepatocyte growth factor, can stimulate cell mitotic division and promote regeneration of blood vessel endothelium and cell migration. In this hypothesis, an adjuvant strategy for chemotherapy is proposed: the anticancer drugs and the cytothesis agents release sequentially, thus the cytothesis agents can work following the anticancer drugs killing tumor cells thoroughly, to promote normal cells proliferation. The programmable release can be achieved through micro-/nano-particles with core-shell structures that simultaneously encapsulate the two different agents in the core and shell regions, respectively. Owing to the advantages of concentrated effects, convenience, and especially its controllability, the hypothesis has potential applications in cancer chemotherapy.